In Brief: Ponatinib (Iclusig) Returns ................................................................. p 8

Important Copyright Message

The Medical Letter® publications are protected by US and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with US and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: Subscriptions, Site Licenses, Reprints
or call customer service at: 800-211-2769

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS
IN BRIEF

Ponatinib (Iclusig) Returns

The October 2013 suspension of marketing and sales of ponatinib (Iclusig – Ariad) for treatment of leukemia¹ has been lifted by the FDA, and the drug is expected to return to the market this month with narrower indications and heightened safety warnings.² The reason for its suspension was a high incidence of thrombotic events, some of them fatal. The new indications limit use of the drug to patients with T315I-positive disease and those “for whom no other tyrosine kinase inhibitor is indicated,” presumably because of resistance or intolerance.
